ASTCT, CIBMTR, Large B-cell lymphoma, Matthew Frank, Miltenyi Biotec, Stanford University
Novel treatment target for lymphoma patients who relapse after CAR-T therapy
Feb 2023: The results of the trial demonstrated that a novel chimeric antigen receptor T-cell therapy elicited a response in adults with advanced large B-cell lymphoma who had relapsed following prior CAR-T. According to stati..
Eli Lilly and Company, FDA, Food and Drug Administration, Jaypirca, Mantle cell lymphoma, MCL, pirtobrutinib
Accelerated approval is granted by FDA to pirtobrutinib for relapsed or refractory mantle cell lymphoma
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
BeiGene USA, BRUKINSA, chronic lymphocytic leukemia, SEQUOIA, small lymphocytic lymphoma
Zanubrutinib is approved by FDA for chronic lymphocytic leukemia or small lymphocytic lymphoma
Feb 2023: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) is approved by FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). SEQUOIA was used to assess effectiveness in CLL/SLL patients who had not recei..
Adcetris, brentuximab vedotin, classical Hodgkin lymphoma, Seagen Inc
Brentuximab vedotin is approved by FDA in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma
November 2022: The combination of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide with brentuximab vedotin (Adcetris, Seagen, Inc.) has been approved by the Food and Drug Administration for use in children an..
FIGHT-203, Incyte Corporation, NCT03011372, Pemazyre, Pemigatinib
Pemigatinib is approved for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement
November 2022: Pemigatinib (Pemazyre, Incyte Corporation) has been licenced by the Food and Drug Administration for use in people with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) that have an altered fibroblast growth..
Breyanzi, Juno Therapeutics, Large B-cell lymphoma, LBCL, TRANSFORM
Lisocabtagene maraleucel is approved by FDA for second-line treatment of large B-cell lymphoma
July 2022: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been approved by the Food and Drug Administration for adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoi..
ELARA trial, follicular lymphoma, Kymriah, NCT03568461, Novartis, Novartis Pharmaceuticals Corporation, Tisagenlecleucel
Tisagenlecleucel is approved by FDA for relapsed or refractory follicular lymphoma
June 2022: After two or more lines of systemic therapy, the FDA awarded tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) expedited approval for adult patients with relapsed or refractory follicular lymphoma (FL).T..
Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma
March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), is a safe and effective first-line therapy for patients wit..
Burkitt lymphoma, Burkitt-like lymphoma, DLBCL, Genentech, Rituxan, Rituximab
Rituximab plus chemotherapy is approved by FDA for pediatric cancer indications
March 2022: The Food and Drug Administration has approved rituximab (Rituxan, Genentech, Inc.) in conjunction with chemotherapy for CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma..
TECARTUS (brexucabtagene autoleucel) – CAR T treatment for relapsed or refractory mantle cell lymphoma
July 25, 2021: Kite, a Gilead Company (Nasdaq: GILD), today announced that the FDA has granted TecartusTM (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor CAR T-cell therapy for ..